The efficacy of ceritinib in patients with ALK-positive non-small cell lung cancer

John Kaczmar; Ranee Mehra

doi:10.1177/1753465815597834

The efficacy of ceritinib in patients with ALK-positive non-small cell lung cancer

John Kaczmar, Ranee Mehra

School of Medicine

Research output: Contribution to journal › Review article › peer-review

3 Scopus citations

Abstract

Research over the last decade has determined that the gene rearrangement involving the anaplastic lymphoma kinase (ALK) gene is an oncogenic driver in approximately 5% of patients with non-small cell lung carcinoma (NSCLC). This review describes the discovery of the ALK translocation, development of ALK directed therapy, and acquired resistance to ALK directed therapy with a focus on the clinical data and efficacy of the most recently approved ALK inhibitor, ceritinib.

Original language	English (US)
Pages (from-to)	236-241
Number of pages	6
Journal	Therapeutic Advances in Respiratory Disease
Volume	9
Issue number	5
DOIs	https://doi.org/10.1177/1753465815597834
State	Published - Oct 2015

Keywords

ALK translocation
NSCLC
ceritinib

ASJC Scopus subject areas

Pulmonary and Respiratory Medicine
Pharmacology (medical)

Access to Document

10.1177/1753465815597834

Cite this

@article{baa35e38948f47fc9d4b51923acac328,

title = "The efficacy of ceritinib in patients with ALK-positive non-small cell lung cancer",

abstract = "Research over the last decade has determined that the gene rearrangement involving the anaplastic lymphoma kinase (ALK) gene is an oncogenic driver in approximately 5% of patients with non-small cell lung carcinoma (NSCLC). This review describes the discovery of the ALK translocation, development of ALK directed therapy, and acquired resistance to ALK directed therapy with a focus on the clinical data and efficacy of the most recently approved ALK inhibitor, ceritinib.",

keywords = "ALK translocation, NSCLC, ceritinib",

author = "John Kaczmar and Ranee Mehra",

year = "2015",

month = oct,

doi = "10.1177/1753465815597834",

language = "English (US)",

volume = "9",

pages = "236--241",

journal = "Therapeutic Advances in Respiratory Disease",

issn = "1753-4658",

publisher = "SAGE Publications Ltd",

number = "5",

}

TY - JOUR

T1 - The efficacy of ceritinib in patients with ALK-positive non-small cell lung cancer

AU - Kaczmar, John

AU - Mehra, Ranee

PY - 2015/10

Y1 - 2015/10

N2 - Research over the last decade has determined that the gene rearrangement involving the anaplastic lymphoma kinase (ALK) gene is an oncogenic driver in approximately 5% of patients with non-small cell lung carcinoma (NSCLC). This review describes the discovery of the ALK translocation, development of ALK directed therapy, and acquired resistance to ALK directed therapy with a focus on the clinical data and efficacy of the most recently approved ALK inhibitor, ceritinib.

AB - Research over the last decade has determined that the gene rearrangement involving the anaplastic lymphoma kinase (ALK) gene is an oncogenic driver in approximately 5% of patients with non-small cell lung carcinoma (NSCLC). This review describes the discovery of the ALK translocation, development of ALK directed therapy, and acquired resistance to ALK directed therapy with a focus on the clinical data and efficacy of the most recently approved ALK inhibitor, ceritinib.

KW - ALK translocation

KW - NSCLC

KW - ceritinib

UR - http://www.scopus.com/inward/record.url?scp=84942584242&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942584242&partnerID=8YFLogxK

U2 - 10.1177/1753465815597834

DO - 10.1177/1753465815597834

M3 - Review article

C2 - 26229087

AN - SCOPUS:84942584242

SN - 1753-4658

VL - 9

SP - 236

EP - 241

JO - Therapeutic Advances in Respiratory Disease

JF - Therapeutic Advances in Respiratory Disease

IS - 5

ER -

The efficacy of ceritinib in patients with ALK-positive non-small cell lung cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this